Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Advanced and/or metastatic solid tumor

- No more than 3 prior regimens for metastatic disease

- Refractory non-Hodgkin's lymphoma

- Clinically or radiologically documented disease

- Patients whose only evidence of disease is tumor marker elevation are not
eligible

- No untreated brain or meningeal metastases

- Patients with radiologic or clinical evidence of stable, treated brain
metastases are eligible provided they are asymptomatic AND have no requirement
for corticosteroids

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Absolute granulocyte count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Creatinine ≤ 1.25 times upper limit of normal (ULN) OR creatinine clearance ≥ 50
mL/min

- Bilirubin normal

- ALT and AST ≤ 2 times ULN (5 times ULN if patient has documented liver metastases)

- Potassium normal

- Calcium normal

- Creatine kinase (CK or CPK) ≤ 2 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction,
including any of the following:

- Significant cardiac event (including symptomatic heart failure or angina) within
the past 3 months or any cardiac disease that, in the opinion of the
investigator, increases the risk for ventricular arrhythmia

- Any history of ventricular arrhythmia, which was symptomatic or required
treatment (CTC grade 3), including multifocal PVCs, bigeminy, trigeminy, or
ventricular tachycardia

- Uncontrolled hypertension

- Previous history of QT prolongation with other medication

- Congenital long QT syndrome

- QT and QTc, with Bazett's correction, unmeasurable or ≥ 460 msec on screening
ECG

- LVEF < 45 % by MUGA for patients with significant cardiac history (i.e.,
myocardial infarction, severe hypertension, or arrhythmia) or prior doxorubicin
(> 450 mg/m²)

- No active or uncontrolled infections

- No serious illness or medical condition that would preclude study compliance

- No peripheral neuropathy > grade 1

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 21 days since prior cytotoxic chemotherapy and recovered (solid tumors)

- At least 21 days since prior palliative radiotherapy and recovered

- Exceptions may be made for low-dose, nonmyelosuppressive radiotherapy

- Prior hormonal, immunologic, biologic, or signal transduction inhibitor therapy
allowed

- At least 14 days since prior major surgery and recovered (no nonhealing wounds)

- At least 4 weeks since prior steroids

- No other concurrent medications which affect QT/QTc and cannot be discontinued

- No other concurrent experimental drugs or anticancer therapy